A surgeon-led conversation about peptides, metabolic optimization, and recovery biology — built for active adults who want to understand their options without being sold a product.
A sixty-minute visit with Dr. Rahman focused on the biology of recovery, resilience, and healthy tissue aging — with particular attention to the compounds and protocols most often asked about by active adults: peptides, metabolic optimization, and the interaction between systemic health and musculoskeletal longevity.
The format is a real clinical conversation, not a wellness intake. We review your history, your imaging if relevant, your training and activity profile, and the specific compounds or approaches you want to understand. You leave with a game plan — what is clinically reasonable for your situation, what is investigational, what the evidence actually shows, and what a sensible next step looks like.
Every consultation is shaped by the patient in front of us, but the conversation typically covers three domains.
BPC-157, TB-500, TB-4 (thymosin beta-4), GHK-Cu, and the body of research on these peptides in tendon, ligament, and soft tissue healing. Dr. Rahman is lead author of a 2026 JAAOS Global review on therapeutic peptides in orthopaedics and presented on BPC-157 and rotator cuff tendinopathy at the Peptide World Congress 2026 in Phoenix.
Ipamorelin, CJC-1295, tesamorelin, and sermorelin — the growth hormone secretagogues. How they differ from administering growth hormone directly, what the safety profiles look like, where the evidence is strongest, and the specific considerations for athletes subject to anti-doping testing.
GLP-1 receptor agonists (semaglutide, tirzepatide) as they relate to joint loading, inflammation, and orthopedic outcomes. Body composition, glycemic control, and inflammation as upstream drivers of cartilage and tendon biology. Discontinuation timing for patients considering surgery.
Most clinicians discussing peptides cannot read your MRI. Dr. Rahman can tell you whether a painful tendon is a candidate for conservative care — or whether it is a retracted tear that no signaling molecule will repair. That distinction changes the entire conversation.
For patients in the gray zone between "optimize" and "operate," the peptide conversation is inseparable from the surgical conversation. The same physician owning both decisions means you get a coherent plan — not two disconnected ones that work against each other.
Dr. Rahman publishes in this field. That means he knows where the evidence is strong, where it is preclinical, where it is hyped, and where the regulatory picture changes the calculus. You get the real read — not the marketing version.
Three things you leave with:
Most longevity and peptide clinics are built around a product line. A compounding pharmacy sends a vial, a nurse practitioner signs the script, you get a six-month supply. The pricing is subscription. The relationship is transactional. The clinical depth is thin.
Chronos is built differently. We are a focused orthopedic practice with a surgeon making the decisions. Peptides are one input into a coherent plan — not a product we are trying to sell you on a recurring schedule. If a peptide is the right tool for your situation, we will say so. If it is not, we will say that too.
The Initial Consultation ($250) is the welcoming front door for any concern. The Longevity Consultation ($500) is the deeper, surgeon-led visit for long-term optimization. Either fee credits toward enrollment within 90 days.
Ongoing longevity guidance, quarterly reassessments, and modality care. Three tiers.
Membership details →For patients with a specific orthopedic problem who want longevity support layered into a structured program.
Programs →Pricing shown covers consultation, membership, and program services. Any medications or therapies, where clinically appropriate, are handled separately through licensed pharmacies and are not sold through this website. All costs are reviewed directly with you before enrollment. Cash-pay practice.
Several compounds people ask about in a longevity consultation — including BPC-157, TB-500, TB-4, and MOTS-c — are not FDA-approved for human use in the United States and carry shifting regulatory classifications. This website does not offer, advertise, or promise any specific compound. The consultation is an educational and clinical conversation: what the evidence shows, what remains investigational, what the current regulatory picture looks like, and what informed consent means for any approach. Any clinical decision is made privately, individually, and only when clinically appropriate.
The regulatory landscape for these compounds changes frequently. We discuss it honestly and current as of your visit, rather than making claims on a web page.
Read the full educational review on peptides and cellular optimization → · See peptide FAQ →
Sixty minutes with a board-certified orthopedic surgeon who has published on this field. A game plan. An honest read. A clear next step.
Book Your Consultation